José Manuel Pérez Ortiz
Professor
Pharmacology
Castilla La Mancha University
Spain
Biography
Dr. José M. Pérez Ortiz has a degree in Biology from the University of Alicante (1998), Biochemistry from Miguel Hernández University (2000) and PhD in Experimental Biomedicine from the University of Castilla-La Mancha (2007). In 2014 he joined the General University Hospital of Ciudad Real as a project manager and with the aim of implementing molecular and cellular biology techniques for basic-clinical experimentation in the areas of oncology, eating disorders and dermatology. He is the author of 20 scientific publications and 1 book. He has presented 26 contributions in international congresses and 31 in national congresses. During his scientific-labor career, he has participated as a researcher in 1 European project, 7 national, 8 autonomic and 4 other entities. In reference to his teaching experience, he is professor of the 3rd year course 'Pharmacology, anesthesia and nutrition' since 2015. He has participated in doctoral, masters, teaching innovation and continuing education courses for health professionals. Tutoring students of the UCLM in master's degree, end-of-grade and extracurricular practice periods, and residents of preventive medicine and public health in their specialty training program. In addition, he is accredited as a professor contracted doctor by the ANECA. He is secretary of the Research Commission of the General University Hospital of Ciudad Real, member of the Committee of Ethics in Animal Experimentation / Body in charge of Animal Welfare, and Associate Editor of the Scientific Bulletin Notes of Science.
Research Interest
Pharmacology, anesthesia and nutrition
Publications
-
Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzó M, Esteve J. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). Journal of the American College of Cardiology. 2013 Jun 11;61(23):2355-62.
-
Pastor MD, GarcÃa-Yébenes I, Fradejas N, Pérez-Ortiz JM, Mora-Lee S, Tranque P, Moro MÃ, Pende M, Calvo S. mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia. Journal of Biological Chemistry. 2009 Aug 14;284(33):22067-78.
